Latest News of SGMO
Sangamo Therapeutics Inc (SGMO) Q3 2024 Earnings Call Highlights: Strategic Advances and ...
By Yahoo! Finance |
1 week ago
The Fabry program expects top-line data by Q2 2025, with the last patient visit in April 2025. FDA's supportive approach for rare diseases allowed an accelerated approval pathway for positive eGFR slo...
Investors in Sangamo Therapeutics (NASDAQ:SGMO) from three years ago are still down 90%, even after 13% gain this past week
By Yahoo! Finance |
2 months ago
Sangamo Therapeutics' share price surged 116% in 3 months, despite a 90% drop over 3 years. Recent gains raise hope, but long-term revenue decline poses risks. Investors should consider diversificatio...